Barclays Reiterates Overweight Rating on Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP)

Market Context

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A operates in the Healthcare sector. The stock currently trades at $429.94 with a market capitalization of $54.4B.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Barclays	Overweight	N/A
Jun 08, 2026	JP Morgan	Overweight	N/A
May 07, 2026	Citigroup	Neutral	N/A
May 07, 2026	UBS	Neutral	N/A
May 07, 2026	Barclays	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View BRKRP Stock Page